Skip to main content

Robalzotan









Robalzotan


From Wikipedia, the free encyclopedia

Jump to navigation
Jump to search



























































Robalzotan
Robalzotan.png
Clinical data
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status

  • In general: uncontrolled


Identifiers
CAS Number

  • 169758-66-1 ☑Y

PubChem CID
  • 3055171
IUPHAR/BPS
  • 72
ChemSpider

  • 2316732 ☒N
UNII
  • I18M56OGME
Chemical and physical data
Formula
C18H23FN2O2
Molar mass 318.174 g/mol
3D model (JSmol)
  • Interactive image

.mw-parser-output .nobold{font-weight:normal}
 ☒N☑Y (what is this?)
  (verify)

Robalzotan (NAD-299, AZD-7371) is a selective antagonist at the 5-HT1A receptor.[1] It was shown to completely reverse the autoreceptor-mediated inhibition of serotonin release induced by the administration of selective serotonin reuptake inhibitors like citalopram in rodent studies.[2] It was subsequently investigated by AstraZeneca as a potential antidepressant but like many other 5-HT1A ligands was discontinued.[3] Later on it was researched for other indications such as irritable bowel syndrome but was dropped once again.[4]



See also[edit]



  • Ebalzotan

  • UH-301



References[edit]





  1. ^ Jerning E, Svantesson GT, Mohell N (1998). "Receptor binding characteristics of [3H]NAD-299, a new selective 5-HT1A receptor antagonist". Eur J Pharmacol. 360 (2–3): 219–225. doi:10.1016/S0014-2999(98)00667-0. PMID 9851589..mw-parser-output cite.citation{font-style:inherit}.mw-parser-output q{quotes:"""""""'""'"}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-limited a,.mw-parser-output .cs1-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}


  2. ^ Arborelius L, Wallsten C, Ahlenius S, Svensson TH (1999). "The 5-HT(1A) receptor antagonist robalzotan completely reverses citalopram-induced inhibition of serotonergic cell firing". Eur J Pharmacol. 382 (2): 133–138. doi:10.1016/S0014-2999(99)00592-0. PMID 10528148.


  3. ^ Mucke HA. (2000). "Robalzotan AstraZeneca". Curr Opin Investig Drugs. 1 (2): 236–240. PMID 11249580.


  4. ^ Drossman DA, Danilewitz M, Naesdal J, Hwang C, Adler J, Silberg DG (October 2008). "Randomized, double-blind, placebo-controlled trial of the 5-HT1A receptor antagonist AZD7371 tartrate monohydrate (robalzotan tartrate monohydrate) in patients with irritable bowel syndrome". The American Journal of Gastroenterology. 103 (10): 2562–9. doi:10.1111/j.1572-0241.2008.02115.x. PMID 18775020.





















Retrieved from "https://en.wikipedia.org/w/index.php?title=Robalzotan&oldid=812126270"





Navigation menu

























(window.RLQ=window.RLQ||).push(function(){mw.config.set({"wgPageParseReport":{"limitreport":{"cputime":"0.848","walltime":"1.042","ppvisitednodes":{"value":5907,"limit":1000000},"ppgeneratednodes":{"value":0,"limit":1500000},"postexpandincludesize":{"value":394329,"limit":2097152},"templateargumentsize":{"value":7119,"limit":2097152},"expansiondepth":{"value":16,"limit":40},"expensivefunctioncount":{"value":2,"limit":500},"unstrip-depth":{"value":1,"limit":20},"unstrip-size":{"value":12952,"limit":5000000},"entityaccesscount":{"value":2,"limit":400},"timingprofile":["100.00% 703.609 1 -total"," 59.14% 416.114 1 Template:Drugbox"," 39.47% 277.746 1 Template:Infobox"," 22.47% 158.134 24 Template:Navbox"," 17.97% 126.441 1 Template:Reflist"," 15.65% 110.105 4 Template:Cite_journal"," 11.90% 83.761 16 Template:Unbulleted_list"," 8.32% 58.564 1 Template:Antidepressants"," 7.62% 53.637 1 Template:Navbox_with_collapsible_groups"," 6.75% 47.517 1 Template:Serotonergics"]},"scribunto":{"limitreport-timeusage":{"value":"0.280","limit":"10.000"},"limitreport-memusage":{"value":5118653,"limit":52428800}},"cachereport":{"origin":"mw1324","timestamp":"20181215065806","ttl":1900800,"transientcontent":false}}});mw.config.set({"wgBackendResponseTime":122,"wgHostname":"mw1275"});});

Popular posts from this blog

Full-time equivalent

さくらももこ

13 indicted, 8 arrested in Calif. drug cartel investigation